Lenalidomide and pomalidomide, which are also commonly used to treat MM, can also upregulate DNAM-1 and NKG2D ligands through the downregulation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) that negatively regulate their transcription [37]. This evidence concerns the gene IKZF1 and Miyoshi myopathy.